Bexarotene prodrug in nanobubble form is inserted directly into the tumor using a flexible catheter. Ultrasound ablation therapy to ‘pop’ the bubbles to release the agent. Credit: University of Illinois
A novel method for repositioning an FDA-approved anti-cancer compound has been discovered, which allows it to specifically target liver cancer tumors. A ‘triple attack’ technique combining chemotherapy, thermal ablation, and hyperthermia provided a highly targeted, yet minimally invasive approach.
“In this study, we re-purposed the topical agent bexarotene (Targretin®) – currently in limited use for cutaneous manifestations of T-cell lymphomas – and re-engineered it for use in solid tumor applications by forming self-assembling nanobubbles,” explained Assistant Prof. Dipanjan Pan...
Read More
Recent Comments